Lewy body disease includes clinically and pathologically defined disorders in which Lewy bodies occur in the nervous system. In recent years, the molecular features of these disorders have been emerging. Several genetic loci have been identified in association with familial Lewy body disease; however, the genetic risks underlying most cases of familial Lewy body disease remain to be discovered. The fact that Lewy bodies stain strongly with antibodies to α-synuclein and that mutations in the α-synuclein gene lead to syndromes in which parkinsonism and dementia occur gives us important clues regarding the biologic processes leading to disease. Pursuit of additional mendelian causes of familial Lewy body disease and study of the factors contributing to the complex phenotypes associated with Lewy body disorders will elucidate underlying disease pathways and, thus, possible targets for therapeutic intervention. (J Geriatr Psychiatry Neurol 2002; 15:000–000).
Get full access to this article
View all access options for this article.
References
1.
1. McKeith IG, Galasko D, Kosaka K, et al., Consensus guidelines for the clinical and pathologic diagnosis of dementia with Lewy bodies (DLB): report of the Consortium on DLB International Workshop. Neurology1996; 47: 1113–1124.
2.
2. McKeith I, Fairbairn A, Perry R, et al., Neuroleptic sensitivity in patients with senile dementia of Lewy body type. BMJ1992; 19: 305: 673–678.
3.
3. Samuel W, Caligiuri M, Galasko D, et al., Better cognitive and psychopathologic response to donepezil in patients prospectively diagnosed as dementia with Lewy bodies: a preliminary study. Int J Geriatr Psychiatry2000; 15: 794–802.
4.
4. Boeve BF, Silber MH, Ferman TJ, et al., REM sleep behavior disorder and degenerative dementia: an association likely reflecting Lewy body disease. Neurology1998; 51: 363–367.
5.
5. Dickson DW., Alpha-synuclein and the Lewy body disorders. Curr Opin Neurol2001; 14: 423–432
6.
6. Katzman R, Galasko D, Saitoh T, et al., Genetic evidence that the Lewy body variant is indeed a phenotypic variant of Alzheimer's disease. Brain Cogn1995; 28: 259–265.
7.
7. Polymeropoulos MH, Lavedan C, Leroy E, et al., Mutation in the alpha-synuclein gene identified in families with Parkinson's disease. Science1997; 276: 2045–2047.
8.
8. Spillantini MG, Schmidt ML, Lee VM, et al., Alpha-synuclein in Lewy bodies. Nature1997; 28: 388: 839–840.
9.
9. Dickson DW, Liu W-K, Hardy J, et al., Glial cytoplasmic inclusions (GCI) of multiple system atrophy (MSA) contain alphasynuclein. Mov Disord1998; 13(Suppl 12): 128.
10.
10. Wakabayashi K, Yoshimoto M, Tsuji S, Takahashi H., Alphasynuclein immunoreactivity in glial cytoplasmic inclusions in multiple system atrophy. Neurosci Lett1998; 249: 180–182.
11.
11. Lippa CF, Schmidt ML, Lee VM-Y, Trojanowski JQ., Antibodies to alpha-synuclein detect Lewy bodies in many Down's syndrome brains with Alzheimer's disease. Ann Neurol1999; 45: 353–357.
12.
12. Arawaka S, Saito Y, Murayama S, Mori H., Lewy body in neurodegeneration with brain iron accumulation type 1 is immunoreactive for alpha-synuclein. Neurology1998; 51: 887–889.
13.
13. Wakabayashi K, Fukushima T, Koide R, et al., Juvenile-onset generalized neuroaxonal dystrophy (Hallervorden-Spatz disease) with diffuse neurofibrillary and Lewy body pathology. Acta Neuropathol (Berl)2000; 99: 331–336.
14.
14. Lowe J, Mayer RJ, Landon M., Ubiquitin in neurodegenerative diseases. Brain Pathol1993; 3: 55–65.
15.
15. Bugiani O, Giaccone G, Piccardo P, et al., Neuropathology of Gerstmann-Straussler-Scheinker disease. Microsc Res Tech2000; 50(1), 10–15.
16.
16. Lippa CF, Fujiwara H, Mann DMA, et al., Lewy bodies contain altered alpha-synuclein in brains of many familial Alzheimer's disease patients with mutations in presenilin and amyloid precursor protein genes. Am J Pathol1998; 153: 1365–1370.
17.
17. Dickson DW, Farrer MJ, Mehta ND, et al., Antibodies to nonamyloid component of plaques (NACP) specifically label Lewy bodies and Lewy neurites, but not other inclusions in neurodegenerative diseases. J Neuropathol Exp Neurol1998; 57: 516.
18.
18. Galvin JE, Lee VM, Trojanowski JQ., Synucleinopathies: clinical and pathological implications. Arch Neurol2001; 58: 186–190.
19.
19. Farrer M, Gwinn-Hardy K, Hutton M, Hardy J., The genetics of disorders with synuclein pathology and parkinsonism. Hum Mol Genet1999; 8: 1901–1905.
20.
20. Golbe LI, Di Iorio G, Sanges G, et al., Clinical genetic analysis of Parkinson's disease in the Contursi kindred. Ann Neurol1998; 40: 767–775.
21.
21. Polymeropoulos MH, Higgins JJ, Golbe LI, et al., Mapping of a gene for Parkinson's disease to chromosome 4q21-q23. Science1996; 15: 274: 1197–1199.
22.
22. Krüger R, Kuhn W, Muller T, et al., Ala30Pro mutation in the gene encoding alpha-synuclein in Parkinson's disease. Nat Genet1998; 18: 106–108.
23.
23. Langston JW, Sastry S, Chan P, et al., Novel alpha-synuclein-immunoreactive proteins in brain samples from the Contursi kindred, Parkinson's, and Alzheimer's disease. Exp Neurol1998; 154: 684–690.
24.
24. Clayton DF, George JM., The synucleins: a family of proteins involved in synaptic function, plasticity, neurodegeneration and disease. Trends Neurosci1998; 21: 249–254.
25.
25. Masliah E, Rockenstein E, Veinbergs I, et al., Dopaminergic loss and inclusion body formation in alpha-synuclein mice: implications for neurodegenerative disorders. Science2000; 18: 287: 1265–1269.
26.
26. Matsuoka Y, Vila M, Lincoln S, et al., Lack of nigral pathology in transgenic mice expressing human α-synuclein driven by the tyrosine hydroxylase promoter. Neurobiol Dis2000; 8: 535–539.
27.
27. Abeliovich A, Schmitz Y, Farinas I, et al., Mice lacking alphasynuclein display functional deficits in the nigrostriatal dopamine system. Neuron2000; 25: 239–252.
28.
28. Feany MB, Bender WW., A Drosophila model of Parkinson's disease. Nature2000; 23: 404: 394–398.
29.
29. Vaughan J, Farrer M, Gasser T, et al, and The European Consortium on Genetic Susceptibility in Parkinson's Disease (GSPD)., Sequencing of the a-synuclein gene in 27 kindreds with familial Parkinson's disease. Hum Mol Genet1998; 7: 751–753.
30.
30. Spellman GG., Report of familial cases of Parkinsonism. Evidence of a dominant trait in a patient's family. JAMA1962; 179: 160–162.
31.
31. Muenter MD, Forno LS, Hornykiewicz O, et al., Hereditary form of parkinsonism–dementia. Ann Neurol1998; 43: 768–781.
32.
32. Gwinn-Hardy K, Mehta ND, Farrer M, et al., Distinctive neuropathology revealed by α-synuclein antibodies in hereditary parkinsonism and dementia linked to chromosome 4p. Acta Neuropathol (Berl)2000; 99: 663–672.
33.
33. Waters CH, Miller CA., Autosomal dominant parkinsonism in a four generation family. Ann Neurol1994; 35: 59–64.
34.
34. Farrer M, Gwinn-Hardy K, Muenter M, et al., A chromosome 4p haplotype segregating with Parkinson's disease and postural tremor. Hum Mol Genet1999; 8: 81–85.
35.
35. Denson MA, Wszolek ZK, Pfeiffer RF, et al., Familial parkinsonism, dementia, and Lewy body disease: study of family G. Ann Neurol1997; 42: 638–643.
36.
36. Wakabayashi K, Hayashi S, Ishikawa A, et al., Autosomal dominant diffuse Lewy body disease. Acta Neuropathol (Berl)1998; 96: 207–210.
38. Ishikawa A, Takahashi H, Tanaka H, et al., Clinical features of familial diffuse Lewy body disease. Eur Neurol1997; 38(Suppl 1), 34–38.
39.
39. Ohara K, Takauchi S, Kokai M, et al., Familial dementia with Lewy bodies (DLB). Clin Neuropathol1999; 18: 232–239.
40.
40. Golbe LI, Lazzarini AM, Schwarz KO, et al., Autosomal dominant parkinsonism with benign course and typical Lewy-body pathology. Neurology1993; 43: 222–227.
41.
41. Wszolek ZK, Cordes M, Calne DB, et al., Hereditary Parkinson disease: report of 3 families with dominant autosomal inheritance. Nervenarzt1993; 64: 331–335.
42.
42. Wszolek ZK, Gwinn-Hardy K, Muenter D, et al., Neuropathology of two members of a German-American kindred (family C) with late onset parkinsonism. Acta Neuropathol (Berl)2002; 103: 334–50
43.
43. Chinnery PF, Taylor GA, Howell N, et al., Mitochondrial DNA haplogroups and susceptibility to AD and dementia with Lewy bodies. Neurology2000; 55: 302–304.
44.
44. Galasko D, Saitoh T, Xia Y, et al., The apolipoprotein E allele epsilon 4 is overrepresented in patients with the Lewy body variant of Alzheimer's disease. Neurology1994; 44: 1950–1951.
45.
45. Armstrong M, Daly AK, Cholerton S, et al., Mutant debrisoquine hydroxylation genes in Parkinson's disease. Lancet1992; 339: 1017–1018.
46.
46. Smith CA, Gough AC, Leigh PN, et al., Debrisoquine hydroxylase gene polymorphism and susceptibility to Parkinson's disease. Lancet1992; 339: 1375–1377.
47.
47. Bordet R, Broly F, Destee A, Libersa C., Genetic polymorphism of cytochrome P450 2D6 in idiopathic Parkinson disease and diffuse Lewy body disease. Clin Neuropharmacol1994; 17: 484–488.
48.
48. Xu W, Liu L, Emson P, et al., The CCTTT polymorphism in the NOS2A gene is associated with dementia with Lewy bodies. Neuroreport2000; 11: 297–299.
49.
49. Singleton AB, Gibson AM, McKeith IG, et al., Nitric oxide synthase gene polymorphisms in Alzheimer's disease and dementia with Lewy bodies. Neurosci Lett2001; 303: 33–36.
50.
50. Trojanowski JQ, Lee VM., Parkinson's disease and related neurodegenerative synucleinopathies linked to progressive accumulations of synuclein aggregates in brain. Parkinsonism Relat Disord2001; 7: 247–251.
51.
51. Baba M, Nakajo S, Tu PH, et al., Aggregation of alpha-synuclein in Lewy bodies of sporadic Parkinson's disease and dementia with Lewy bodies. Am J Pathol1998; 152: 879–884.
52.
52. Farrer M, Gwinn-Hardy K, Hutton M, Hardy J., The genetics of disorders with synuclein pathology and parkinsonism. Hum Mol Genet1999; 8: 1901–1905.
53.
53. Hardy J, Gwinn-Hardy K., Neurodegenerative disease: a different view of diagnosis. Mol Med Today1999; 5: 514–517.
54.
54. Leroy E, Boyer R, Auburger G., The ubiquitin pathway in Parkinson's disease. Nature1998; 395: 451–452.
55.
55. Hardy J., Pathways to primary neurodegenerative disease. Ann N Y Acad Sci2000; 924: 29–34.
56.
56. Kruger R, Kuhn W, Leenders KL, et al., Familial parkinsonism with synuclein pathology: Clinical and PET studies of A30P mutation carriers. Neurology2001; 56: 1355–1362.
57.
57. Kitada T, Asakawa S, Hattori N, et al., Mutations in the parkin gene cause autosomal recessive juvenile parkinsonism. Nature1998; 392: 605–608.
58.
58. Gasser T, Muller-Myhsok B, Wszolek ZK, et al., A susceptibility locus for Parkinson's disease maps to chromosome 2p13. Nat Genet1998; 18: 262–265.
59.
59. Goate AM, Chartier-Harlin MC, Mullan M, et al., Segregation of a missense mutation in the amyloid precursor protein gene with familial Alzheimer's disease. Nature1991; 349: 704–706.
60.
60. Sherrington R, Rogaev EI, Liang Y, et al., Cloning of a gene bearing missense mutations in early-onset familial Alzheimer's disease. Nature1995; 375: 754–760.
61.
61. Levy-Lahad E, Wasco W, Poorkaj P, et al., Candidate gene for the chromosome 1 familial Alzheimer's disease locus. Science1995; 269: 973–977.
62.
62. Hansen LA, Samuel W., Criteria for Alzheimer's disease and the nosology of dementia with Lewy bodies. Neurology1997; 48: 126–132.
63.
63. Taylor TD, Litt M, Kramer P, et al., Homozygosity mapping of Hallervorden-Spatz syndrome to chromosome 20p12.3-p13. Nat Genet1996; 14: 479–481.
64.
64. Valente EM, Bentivoglio AR, Dixon PH, et al., Localization of a novel locus for autosomal recessive early-onset parkinsonism, PARK6, on human chromosome 1p35-p36. Am J Hum Genet2001; 68: 895–900.
65.
65. Van Duijn CM, Dekker MCJ, Bonifati V, et al., PARK7, a novel locus for autosomal recessive early-onset parkinsonism on chromosome 1p36. Am J Hum Genet2001; 69: 629–634.
66.
66. Valente EM, Brancati F, Ferraria A, et al., PARK6 is a common cause of familial parkinsonism. Ann Neurol2002; 51: 14–18.
67.
67. Hicks A, Petursson H, Jonsson T, et al., A susceptibility gene for late-onset idiopathic Parkinson's disease successfully mapped. Am J Hum Genet2001; 69: 123–200.
68.
68. Sveinbjornsdottir S, Hicks AA, Jonsson T, et al., Familial aggregation of Parkinson's disease in Iceland. N Engl J Med2000; 343: 1765–1770.
69.
69. Leroy E, Boyer R, Auburger G., The ubiquitin pathway in Parkinson's disease. Nature1998; 395: 451–452.
70.
70. Hutton M, Lendon CL, Rizzu P, et al., Association of missense and 51-splice-site mutations in tau with the inherited dementia FTDP-17. Nature1998; 393: 702–705.
71.
71. Shah AB, Chernov I, Zhang HT, et al., Identification and analysis of mutations in the Wilson diseases gene (ATP7B): population frequencies, genotype-phenotype correlation, and functional analyses. Am J Hum Genet1997; 61: 317–328.
72.
72. Wilhelmsen KC, Weeks DE, Nygaard TG, et al., Genetic mapping of “Lubag” (X-linked dystonia-parkinsonism) in a Filipino kindred to the pericentromeric region of the X chromosome. Ann Neurol1991; 29: 124–131.
73.
73. Schmitt HP, Emser W, Heimes C., Familial occurrence of amyotrophic lateral sclerosis, parkinsonism, and dementia. Ann Neurol1984; 16: 642–648.
74.
74. Rosenberg RN, Nyhan WL, Bay C, Shore P., Autosomal dominant striatonigral degeneration. A clinical, pathologic, and biochemical study of a new genetic disorder. Neurology1976; 26: 703–714.
75.
75. Sutton JP, Pulst SM., Atypical parkinsonism in a family of Portuguese ancestry: absence of CAG repeat expansion in the MJD1 gene. Neurology1997; 48: 1285–1290.
76.
76. Farrer M, Chan P, Chen R, et al., Lewy bodies and parkinsonism in families with parkin mutations. Ann Neurol2001; 50: 293–300.
